Kamada (KMDA) Q2 2026 earnings review
Record Top-Line Meets Strong Operating Leverage
Kamada delivered a decisive rebound in Q2 2026, generating record revenues of $54.9M (+23% YoY) and putting to rest concerns over Q1's logistical delays. Top-line acceleration, coupled with strict operating expense control, drove Adjusted EBITDA up 29% YoY to $14.1M. Crucially, the company validated its vertical integration strategy by securing a three-year, $50M agreement for normal source plasma (NSP) sales, slated to begin in Q4 2026. While gross margins slightly compressed, the sheer volume growth and H1 operating cash flow of $17.8M (+137% YoY) cement the company's ability to fund its M&A and dividend goals internally.
🐂 Bull Case
The new $50M, 3-year supply agreement proves Kamada can successfully monetize its Texas plasma collection centers, adding a highly visible and guaranteed revenue stream starting in H2 2026.
Despite gross margin headwinds, disciplined expense management held Q2 OPEX to $13.0M against a massive revenue spike, allowing Net Income to accelerate 26% YoY to $9.3M.
🐻 Bear Case
Gross margin fell from 45% in H1 2025 to 42% in H1 2026, driven by an unfavorable product and regional sales mix that is eating into raw unit profitability.
Management had previously signaled early 2026 for potential M&A transactions to supplement organic growth, but deals remain absent despite a healthy $70.1M cash balance.
⚖️ Verdict: 🟢
Bullish. Kamada effectively erased Q1's shipping-delay weakness with aggressive Q2 volume expansion. The signing of a $50M plasma deal is a concrete, transformative milestone that de-risks future cash flow targets.
Key Themes
Vertical Integration Yields $50M Agreement
Kamada's strategic shift toward vertical integration is officially paying off. The company signed a 3-year, $50M agreement to supply normal source plasma (NSP) to a leading biopharma firm. With the Houston and San Antonio centers scaling toward their $8-10M individual peak capacities, this confirms the viability of a high-margin, predictable secondary business line that reduces reliance on unpredictable 3rd-party plasma suppliers.
Proprietary Portfolio Accelerating
The Proprietary Products segment was the heavy lifter in Q2, generating $47.7M (up 24% YoY). KEDRAB (U.S.), VARIZIG, and HEPAGAM drove the momentum. This proves that Q1's sluggish 3% growth in this segment was indeed an anomaly tied to logistical constraints rather than a structural demand drop.
Gross Margin Story Contradicts EBITDA Gains
While the 29% jump in Adjusted EBITDA dominates the headline, underlying gross profitability decelerated. Gross margin for Q2 dropped to 41% (vs. 42% in 25Q2), and the H1 gap is steeper (42% vs 45% in H1 2025). This contradicts the narrative of an increasingly profitable product mix and shows the bottom-line growth relied entirely on volume absorption and capped OPEX ($13.0M vs $11.9M).
Technological Upgrade: FDA Approves In-House RFFIT Lab
Kamada secured FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. By bringing the gold-standard neutralizing test for rabies-neutralizing antibodies internally, the company improves supply chain agility and quality control for its lead product, KEDRAB.
Geopolitical Logistics Risk Remains
Kamada noted that the Middle East conflict continues to threaten international trade. While the Q1 2026 $2.4M shipment delay was resolved in April, Kamada remains heavily exposed to global flight limitations for supplying ex-U.S. territories and securing timely supply runs.
Distribution Segment Continues Steady Expansion
Distribution revenues accelerated slightly, up 14% YoY in Q2 to $7.2M. Growth is supported by the ongoing rollout of biosimilars in Israel and expansion into the MENA region. Two additional biosimilars are slated to launch in Q3 2026, keeping Kamada on track for its $15M-$20M annual target within 4-5 years.
Other KPIs
Accelerating significantly from $7.5M in H1 2025 (+137%). Demonstrates Kamada's ability to convert increased net income into robust cash generation, comfortably funding its ongoing $14.4M annual dividend obligations.
Stable position, despite paying out a $14.4M dividend in April. Cash dipped slightly from $75.5M at the end of 2025, but liquidity remains exceptionally strong for future M&A execution.
Decelerating from $7.5M in H1 2025 (-41%). This structural drop in overhead is driven by the discontinuation of the Phase 3 InnovAATe clinical trial, permanently lowering the R&D run-rate.
Guidance
Stable. The company maintained its guidance. At the midpoint ($202.5M), this implies a 12% YoY acceleration in organic top-line growth. With $100.2M recorded in H1, Kamada sits exactly at 50% of its target, highly de-risking the second half.
Stable. Maintained guidance implies a 23% YoY growth rate at the midpoint ($51.5M). Having banked $25.7M in H1, the company is perfectly on pace to achieve this record profitability.
Key Questions
Gross Margin Dynamics
With gross margins stepping down to 41% in Q2 from 42% a year ago, how much of this is structural territory mix versus temporary product mix? Where do you see gross margin normalizing in 2027?
Plasma Supply Deal Details
Regarding the new 3-year, $50M NSP agreement: what is the cadence of revenue recognition we should expect? Is it evenly distributed across the 12 quarters starting in Q4 2026?
M&A Timeline Check
Management had previously signaled early 2026 as a window for closing an M&A transaction. Given the robust $70M cash pile, what are the current valuation hurdles delaying a deal?
CYTOGAM Utilization Update
With the recent ISHLT 2026 presentation on CYTOGAM, are you seeing any immediate inflections in hospital formulary adoption or post-transplant utilization rates in Q3 so far?